AzurRx BioPharma (NASDAQ:AZRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, Zacks.com reports. The firm presently has a $1.00 price objective on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 18.72% from the stock’s previous close.
According to Zacks, “Azurrx Biopharma, Inc. is a biopharmaceutical company. It focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company’s product pipeline consists of MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency and AZX1101, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. Azurrx Biopharma, Inc. is headquartered in New York City. “
Several other equities research analysts have also recently weighed in on the company. Maxim Group began coverage on AzurRx BioPharma in a research report on Thursday, April 1st. They set a “buy” rating and a $3.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of AzurRx BioPharma in a research note on Wednesday, April 14th. Roth Capital decreased their target price on AzurRx BioPharma from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, April 1st. Finally, Dawson James downgraded AzurRx BioPharma from a “buy” rating to a “neutral” rating in a report on Wednesday, January 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $2.88.
An institutional investor recently bought a new position in AzurRx BioPharma stock. Renaissance Technologies LLC bought a new stake in shares of AzurRx BioPharma, Inc. (NASDAQ:AZRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 186,200 shares of the company’s stock, valued at approximately $181,000. Renaissance Technologies LLC owned 0.25% of AzurRx BioPharma at the end of the most recent quarter. Institutional investors and hedge funds own 5.14% of the company’s stock.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc, a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients).
Read More: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.